Edition:
India

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

120.05USD
18 Jan 2019
Change (% chg)

$2.01 (+1.70%)
Prev Close
$118.04
Open
$118.51
Day's High
$120.54
Day's Low
$115.50
Volume
78,324
Avg. Vol
103,863
52-wk High
$325.58
52-wk Low
$92.00

Chart for

About

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product,... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $586.42
Shares Outstanding(Mil.): 12.50
Dividend: --
Yield (%): --

Financials

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

18 Sep 2018

U.S. hedge funds bet on retail, tech in second-quarter as economy sizzled

Prominent hedge fund managers appeared to make big second-quarter bets that the U.S. economy would continue to expand despite increasing concerns about a broadening trade dispute between the United States and China, regulatory filings showed Tuesday. | Video

15 Aug 2018

U.S. hedge funds bet on retail, tech in second quarter as economy sizzled

Prominent hedge fund managers appeared to make big second-quarter bets that the U.S. economy would continue to expand despite increasing concerns about a broadening trade dispute between the United States and China, regulatory filings showed Tuesday.

15 Aug 2018

WRAPUP 2-U.S. hedge funds bet on retail, tech in Q2 as economy sizzled

Aug 14 Prominent hedge fund managers appeared to make big second-quarter bets that the U.S. economy would continue to expand despite increasing concerns about a broadening trade dispute between the United States and China, regulatory filings showed Tuesday.

15 Aug 2018

Earnings vs. Estimates